

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/133348 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 38/18 (2006.01)
A61K 31/713 (2006.01) A61K 38/26 (2006.01)

(21) International Application Number:

PCT/EP2024/088248

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23219939.8 22 December 2023 (22.12.2023) EP
PCT/EP2024/052934
06 February 2024 (06.02.2024) EP
24192162.6 31 July 2024 (31.07.2024) EP
PCT/EP2024/086234
13 December 2024 (13.12.2024) EP

(71) Applicant: **E-THERAPEUTICS PLC** [GB/GB]; 4 King-
dom Street, Paddington Central, London W2 6BD (GB).

(72) Inventors: **WAYNE PURSELL, Natalie**; c/o e-therapeu-
tics plc, 4 Kingdom Street, Paddington Central, London W2
6BD (GB). **VICTOR WHITMORE, Alan**; c/o e-therapeu-
tics plc, 4 Kingdom Street, Paddington Central, London
W2 6BD (GB). **MALANDRAKI-MILLER, Sophia**; c/o
e-therapeutics plc, 4 Kingdom Street, Paddington Central,
London W2 6BD (GB). **DE SANTIAGO, Ines**; c/o e-thera-
peutics plc, 4 Kingdom Street, Paddington Central, London
W2 6BD (GB). **SAGINC GIANNOUSTAS, Gaye**; c/o e-
therapeutics PLC, 4 Kingdom Street, Paddington Central,
London W2 6BD (GB).

(74) Agent: **CMS CAMERON MCKENNA NABARRO
OLSWANG LLP**; Cannon Place 78 Cannon Street, London
EC4N 6AF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: INHIBITORS OF EXPRESSION AND/OR FUNCTION

(57) Abstract: The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a metabolic disease or disorder, such as a metabolic disease or disorder associated with non-alcoholic fatty liver disease (NAFLD) and/or obesity and/or a disease or disorder associated with adipogenesis.

WO 2025/133348 A1